Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics ( (CORT) ) has shared an announcement.
Corcept Therapeutics reported a 48% boost in third-quarter revenue, reaching $182.5 million, and upgraded its 2024 revenue guidance. The company is on track to submit a New Drug Application for relacorilant, a promising treatment for Cushing’s syndrome, supported by successful trials showing significant patient improvements. With plans to release additional study data and a robust cash reserve, Corcept is poised for transformative growth in treating endocrinologic and oncologic conditions.
See more data about CORT stock on TipRanks’ Stock Analysis page.